PRNewsWire
05 Jun 2026, 19:45 UTC · 1h ago
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewsWire
05 Jun 2026, 19:45 UTC · 1h ago
Story key points
1 claims · impact-rated
Law firm Halper Sadeh LLC is investigating whether officers and directors of Metagenomi Therapeutics, Inc. (NASDAQ: MGX) breached their fiduciary duties to shareholders. — Investigations into fiduciary breaches create legal uncertainty and potential governance risks, which typically weigh on a company's stock price.
-0.30Ticker attribution
Model heads
The company is under investigation by a law firm for potential breaches of fiduciary duties by its officers and directors.
The company is under investigation by a law firm for potential breaches of fiduciary duties by its officers and directors.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is under investigation by a law firm for potential breaches of fiduciary duties by its officers and directors.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
